Peregrin Inhibitors belong to a distinctive chemical class characterized by their unique molecular structure and remarkable inhibitory properties. These inhibitors are primarily designed to modulate specific cellular processes by selectively targeting key enzymes or proteins involved in critical pathways. The term Peregrin reflects the dynamic and exploratory nature of these inhibitors, as they traverse intricate biochemical landscapes within the cellular milieu. The chemical architecture of Peregrin Inhibitors is characterized by a central scaffold that serves as the core framework, with various functional groups strategically arranged to enhance binding affinity and specificity to their biological targets.
Peregrin Inhibitors is their versatile mechanism of action, often involving the disruption of crucial protein-protein interactions or interference with enzymatic activity. This class of inhibitors is meticulously engineered to engage with the intricate three-dimensional structures of target biomolecules, leading to the modulation of downstream cellular events. The structural diversity within the Peregrin Inhibitor class allows for tailored design and optimization, enabling researchers to fine-tune their inhibitory properties for specific biological applications. The ongoing research and development in this field aim to unravel the full spectrum of cellular processes that can be influenced by Peregrin Inhibitors, offering insights into fundamental biological mechanisms and paving the way for novel avenues in chemical biology and basic research.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
A selective inhibitor that binds to the ATP-binding site of CDK2, preventing phosphorylation and subsequent cell cycle progression. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Targets the ATP-binding site of CDK2, hindering the kinase activity essential for cell cycle regulation. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Alters the function of CDK2 by competing with ATP at the nucleotide binding site, leading to inhibition of kinase activity. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Interacts with the ATP-binding pocket of CDK2, resulting in a decrease in kinase enzymatic activity. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
Inhibits CDK2 by stabilizing the inactive form of the enzyme, which disrupts the cell cycle. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
A potent inhibitor that binds to the ATP pocket of CDK2, leading to an arrest in cell cycle. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
Binds competitively to the ATP-binding site of CDK2, reducing its kinase activity and affecting cell cycle progression. | ||||||
AT7519 | 844442-38-2 | sc-364416 sc-364416A sc-364416B sc-364416C | 5 mg 10 mg 100 mg 1 g | $291.00 $341.00 $1046.00 $3126.00 | 1 | |
Inhibits CDK2 by occupying its ATP-binding site, which impedes the phosphorylation of its substrates. | ||||||
NU 6140 | 444723-13-1 | sc-202531 | 5 mg | $147.00 | 1 | |
Acts on the ATP-binding site of CDK2, decreasing its activity and affecting downstream cellular processes. | ||||||
BMS-265246 | 582315-72-8 | sc-364440 sc-364440A | 5 mg 10 mg | $304.00 $555.00 | ||
A CDK2 inhibitor that binds to the ATP site, preventing the activation of the kinase and influencing cell division. | ||||||